ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Eli Lilly and Daiichi Sankyo side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Eli LillyDaiichi Sankyo
studies on the registry2,262499
open to participants now17337
phase 3 studies under way10421
reach primary completion within a year10411
programswith a study of their own in two years93+3 named only20

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseEli LillyDaiichi Sankyo
Phase 1

Eli Lilly: 42 of its 93 programs at phase 1

  1. LY4256984phase 1
  2. LY3981314phase 1
  3. LY4167586phase 1
  4. LY4405094phase 1
  5. LY3873862phase 1

and 37 more — sign in to see them all

45%

Daiichi Sankyo: 7 of its 20 programs at phase 1

  1. DS1025Aphase 1
  2. DS3610Aphase 1
  3. DS5361Bphase 1
  4. DS9051Bphase 1
  5. valemetostatphase 1

and 2 more — sign in to see them all

35%
Phase 2

Eli Lilly: 28 of its 93 programs at phase 2

  1. macupatidephase 2
  2. LY4065967phase 2
  3. zotemtegrastphase 2
  4. LY4515100phase 2
  5. LY4005130phase 2

and 23 more — sign in to see them all

30%
25%
Phase 3

Eli Lilly: 13 of its 93 programs at phase 3

  1. orforglipronphase 3
  2. eloralintidephase 3
  3. brenipatidephase 3
  4. retatrutidephase 3
  5. Imlunestrantphase 3

and 8 more — sign in to see them all

14%

Daiichi Sankyo: 4 of its 20 programs at phase 3

  1. trastuzumab deruxtecanphase 3
  2. datopotamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3
  4. raludotatug deruxtecanphase 3
20%
Approved, new studies

Eli Lilly: 10 of its 93 programs at approved, new studies

  1. Tirzepatideapproved, new study
  2. abemaciclibapproved, new study
  3. pirtobrutinibapproved, new study
  4. selpercatinibapproved, new study
  5. donanemabapproved, new study

and 5 more — sign in to see them all

11%

Daiichi Sankyo: 4 of its 20 programs at approved, new studies

  1. quizartinibapproved, new study
  2. bempedoic acidapproved, new study
  3. Ezetimibeapproved, new study
  4. Atorvastatinapproved, new study
20%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Eli Lilly49 readouts · 5 phase 3

Eli Lilly, Nov ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. abemaciclibapproved, new study · Nov 0 · NCT07818967
  2. BPL-003phase 2 · Nov 0 · NCT05660642
  3. brenipatidephase 3 · Nov 0 · NCT06606106
  4. LY3938577phase 2 · Nov 0 · NCT07215312
  5. LY4515100phase 2 · Nov 0 · NCT07511816

and 2 more — sign in to see them all

Eli Lilly, Dec ’26: 5 programs whose next study reaches primary completion

  1. eloralintidephase 3 · Dec 0 · NCT07738614
  2. GIPR Agonist LY3537021phase 2 · Dec 0 · NCT07169851
  3. LY4167586phase 1 · Dec 0 · NCT07225556
  4. ORN252phase 1 · Dec 0 · NCT07439796
  5. ORX750phase 2 · Dec 0 · NCT06752668

Eli Lilly, Jan ’27: 2 programs whose next study reaches primary completion

  1. LY4355756phase 1 · Jan 0 · NCT07765498
  2. parunoflastphase 2 · Jan 0 · NCT07867340

Eli Lilly, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. LY3981314phase 1 · Feb 0 · NCT07005284
  2. mirikizumabapproved, new study · Feb 0 · NCT07446101
  3. orforglipronphase 3 · Feb 0 · NCT06672549

Eli Lilly, Mar ’27: 3 programs whose next study reaches primary completion

  1. lepodisiranphase 3 · Mar 0 · NCT07914738
  2. macupatidephase 2 · Mar 0 · NCT07215559
  3. solbinsiranphase 2 · Mar 0 · NCT07269210

Eli Lilly, Apr ’27: 3 programs whose next study reaches primary completion

  1. Anti-BAFF-R/Anti-CD3 Bispecific Antibody LY4152199phase 1 · Apr 0 · NCT07101328
  2. LY4065967phase 2 · Apr 0 · NCT05986292
  3. olomorasibphase 3 · Apr 0 · NCT04956640

Eli Lilly, May ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. clazakizumabphase 2 · May 0 · NCT07783802
  2. lebrikizumabapproved, new study · May 0 · NCT06338995
  3. LY4005130phase 2 · May 0 · NCT07533019
  4. nisotirostidephase 2 · May 0 · NCT06897475
  5. zotemtegrastphase 2 · May 0 · NCT07186101

Eli Lilly, Jun ’27: 4 programs whose next study reaches primary completion

  1. LY3839056 IVphase 1 · Jun 0 · NCT07945314
  2. LY4395089phase 2 · Jun 0 · NCT07483099
  3. vepugratinibphase 3 · Jun 0 · NCT05614739
  4. ORX489phase 1 · Jun 30 · NCT07413666

Eli Lilly, Jul ’27: 2 programs whose next study reaches primary completion

  1. LY4057996phase 1 · Jul 0 · NCT06945406
  2. LY4226695phase 1 · Jul 0 · NCT07767487

Eli Lilly, Aug ’27: 7 programs whose next study reaches primary completion

  1. Imlunestrantphase 3 · Aug 0 · NCT07918859
  2. LY3439539phase 1 · Aug 0 · NCT07598370
  3. LY4088044phase 1 · Aug 0 · NCT07090785
  4. LY4256984phase 1 · Aug 0 · NCT07100119
  5. LY4302814phase 1 · Aug 0 · NCT07566338

and 2 more — sign in to see them all

Eli Lilly, Sep ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. LY3945262phase 1 · Sep 0 · NCT07943091
  2. LY4066708phase 1 · Sep 0 · NCT07046559
  3. LY4329090phase 1 · Sep 0 · NCT07808073
  4. mazdutidephase 2 · Sep 0 · NCT06143956
  5. naperiglipronphase 2 · Sep 0 · NCT06143956

and 1 more — sign in to see them all

Eli Lilly, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abdenoflastphase 2 · Oct 0 · NCT06836232
  2. pirtobrutinibapproved, new study · Oct 0 · NCT05254743
Daiichi Sankyo3 readouts · 1 phase 3·

Daiichi Sankyo, Dec ’26: 1 program whose next study reaches primary completion

  1. raludotatug deruxtecanphase 3 · Dec 30 · NCT04707248
····

Daiichi Sankyo, May ’27: 1 program whose next study reaches primary completion

  1. quizartinibapproved, new study · May 1 · NCT03793478
····

Daiichi Sankyo, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. trastuzumab deruxtecanphase 3 · Oct 1 · NCT05950945
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Eli Lilly

New programs 8

Reached a new phase 2

Study stopped 0

None

Primary completion later 9

Daiichi Sankyo

New programs 1

  • olomorasibphase 2 · first study · Oct 16 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Where they overlap

Conditions where at least two of them have programs: 16 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionEli LillyDaiichi Sankyo
Carcinoma, Non-Small-Cell Lungboth · compare here

Eli Lilly in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. olomorasibphase 3
  2. Anti-PTK7/Exatecan Antibody-drug Conjugate LY4175408phase 1
  3. abemaciclibapproved, new study
  4. selpercatinibapproved, new study

Their studies: Eli Lilly’s studies of Carcinoma, Non-Small-Cell Lung in search

Diabetes Mellitus, Type 2both · compare here

Eli Lilly in Diabetes Mellitus, Type 2: 10 programs

  1. orforglipronphase 3
  2. retatrutidephase 3
  3. macupatidephase 2
  4. naperiglipronphase 2
  5. mazdutidephase 2

and 5 more — sign in to see them all

Their studies: Eli Lilly’s studies of Diabetes Mellitus, Type 2 in search

Daiichi Sankyo in Diabetes Mellitus, Type 2: 1 program

  1. Atorvastatinapproved, new study

Their studies: Daiichi Sankyo’s studies of Diabetes Mellitus, Type 2 in search

Breast Neoplasmsboth · compare here

Eli Lilly in Breast Neoplasms: 4 programs

  1. Imlunestrantphase 3
  2. tersolisibphase 3
  3. GRPR-targeting Radioconjugate LY4257496phase 1
  4. abemaciclibapproved, new study

Their studies: Eli Lilly’s studies of Breast Neoplasms in search

Daiichi Sankyo in Breast Neoplasms: 3 programs

  1. trastuzumab deruxtecanphase 3
  2. datopotamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3

Their studies: Daiichi Sankyo’s studies of Breast Neoplasms in search

Renal Insufficiencyboth · compare here

Eli Lilly in Renal Insufficiency: 6 programs

  1. olomorasibphase 3
  2. tersolisibphase 3
  3. lepodisiranphase 3
  4. muvalaplinphase 3
  5. pirtobrutinibapproved, new study

and 1 more — sign in to see them all

Their studies: Eli Lilly’s studies of Renal Insufficiency in search

Daiichi Sankyo in Renal Insufficiency: 1 program

  1. olomorasibphase 2

Their studies: Daiichi Sankyo’s studies of Renal Insufficiency in search

Atherosclerosisboth · compare here

Eli Lilly in Atherosclerosis: 5 programs

  1. retatrutidephase 3
  2. lepodisiranphase 3
  3. muvalaplinphase 3
  4. VERVE-102phase 2
  5. clazakizumabphase 2

Their studies: Eli Lilly’s studies of Atherosclerosis in search

Daiichi Sankyo in Atherosclerosis: 1 program

  1. Ezetimibeapproved, new study

Their studies: Daiichi Sankyo’s studies of Atherosclerosis in search

Dyslipidemiasboth · compare here

Eli Lilly in Dyslipidemias: 1 program

  1. solbinsiranphase 2

Their studies: Eli Lilly’s studies of Dyslipidemias in search

Daiichi Sankyo in Dyslipidemias: 3 programs

  1. rosuvastatinphase 1
  2. bempedoic acidapproved, new study
  3. Atorvastatinapproved, new study

Their studies: Daiichi Sankyo’s studies of Dyslipidemias in search

Hepatic Insufficiencyboth · compare here

Eli Lilly in Hepatic Insufficiency: 3 programs

  1. eloralintidephase 3
  2. Imlunestrantphase 3
  3. olomorasibphase 3

Their studies: Eli Lilly’s studies of Hepatic Insufficiency in search

Daiichi Sankyo in Hepatic Insufficiency: 1 program

  1. olomorasibphase 2

Their studies: Daiichi Sankyo’s studies of Hepatic Insufficiency in search

Neoplasm Metastasisboth · compare here

Eli Lilly in Neoplasm Metastasis: 1 program

  1. abemaciclibapproved, new study

Their studies: Eli Lilly’s studies of Neoplasm Metastasis in search

Neoplasmsboth · compare here

Eli Lilly in Neoplasms: 3 programs

  1. LY4066708phase 1
  2. LY4214835phase 1
  3. LY4336619phase 1

Their studies: Eli Lilly’s studies of Neoplasms in search

Daiichi Sankyo in Neoplasms: 1 program

  1. patritumab deruxtecanphase 3

Their studies: Daiichi Sankyo’s studies of Neoplasms in search

Hypertensionboth · compare here

Eli Lilly in Hypertension: 1 program

  1. orforglipronphase 3

Their studies: Eli Lilly’s studies of Hypertension in search

Daiichi Sankyo in Hypertension: 2 programs

  1. rosuvastatinphase 1
  2. Ezetimibeapproved, new study

Their studies: Daiichi Sankyo’s studies of Hypertension in search

Cardiovascular Diseasesboth · compare here

Eli Lilly in Cardiovascular Diseases: 1 program

  1. dulaglutideapproved, new study

Their studies: Eli Lilly’s studies of Cardiovascular Diseases in search

Daiichi Sankyo in Cardiovascular Diseases: 1 program

  1. Atorvastatinapproved, new study

Their studies: Daiichi Sankyo’s studies of Cardiovascular Diseases in search

Colorectal Neoplasmsboth · compare here

Eli Lilly in Colorectal Neoplasms: 1 program

  1. olomorasibphase 3

Their studies: Eli Lilly’s studies of Colorectal Neoplasms in search

Daiichi Sankyo in Colorectal Neoplasms: 1 program

  1. olomorasibphase 2

Their studies: Daiichi Sankyo’s studies of Colorectal Neoplasms in search

Show all 16

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Eli Lilly 50 of 93 · Daiichi Sankyo 14 of 20 programs (33 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Eli Lilly: 3).